Sign in

    Drewry Park

    Vice President and Senior Analyst at Leerink Partners

    Drewry Park is a Vice President and Senior Analyst at Leerink Partners, specializing in equity research across the healthcare sector, particularly biopharmaceuticals and medical technology. He provides detailed coverage of companies such as Humana, Xeris Biopharma, and Aquestive Therapeutics, with a consistent record of accurate stock recommendations supported by public platforms. Park began his career in the healthcare banking field and advanced to his current analyst role after joining Leerink Partners, leveraging prior experience at other major financial institutions. He holds relevant FINRA securities licenses and is recognized for his analytical rigor and strong client advisory, consistently delivering competitive returns for investors.

    Drewry Park's questions to Fulcrum Therapeutics (FULC) leadership

    Drewry Park's questions to Fulcrum Therapeutics (FULC) leadership • Q3 2024

    Question

    Drewry Park, on for Joseph Schwartz at Leerink Partners, requested an update on PIONEER trial site activation, referencing a previous presentation and asking about progress toward the goal of 20 sites.

    Answer

    Executive Alexander Sapir confirmed the goal to have 20 sites activated by year-end, noting a recent investigator meeting included 15 sites. Executive Iain Fraser added that many sites have been activated since the EHA meeting and that the remaining identified sites are expected to be onboarded in the coming months. New sites are also being engaged for future studies.

    Ask Fintool Equity Research AI